Review of ISPE's Baseline Guide for Oral Solid Dosage Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Review of ISPE's Baseline Guide for Oral Solid Dosage Forms
The author outlines the key concepts of ISPE's recently revised Baseline Pharmaceutical Guide for New and Renovated Facilities. This article is part of a special supplement on Excipients and Solid Dosage.


Pharmaceutical Technology
Issue 34, pp. s6-s12


GETTY IMAGES
Oral solid dosage (OSD) forms are the most common dosage forms for patients worldwide, and the use of OSD forms (i.e., tablets, capsules, or powders) is likely to increase as access to medical care expands on a worldwide basis. As a result, OSD production in established markets such as the United States and Western Europe is likely to increase as is production in emerging markets such as India, China, Brazil, Mexico, and South Korea. Pharmaceutical companies may make product internally or use contract manufacturers, which use multipurpose production facilities. At the same time, highly active and highly hazardous substances are becoming more and more part of drug development and, therefore, of manufacturing processes. The term highly hazardous substances refers to cytotoxic, cytostatic, teratogenic, mutagenic, or retrotoxic products. These factors have changed the picture of pharmaceutical production in recent years and will continue to play a role in global pharmaceutical production in the future.

To address these issues, the International Society for Pharmaceutical Engineering (ISPE) released a revised Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities–Volume 2 Oral Solid Dosage Forms in November 2009 (1). More than 30 industry professionals worked on the OSD guide for more than five years through a partnership with the US Food and Drug Administration and European Medicines Agency (EMA) to develop a common understanding and interpretation of good manufacturing practice (GMP) requirements for production facilities. The purpose of the ISPE OSD guide is to support the design and construction of renovated and new facilities.

Key concepts

The recently revised ISPE OSD guide has several key elements:
  • Proper application of facility design and procedures to assist with GMP compliance
  • A risk-based approach
  • Non-GMP technology and its effect on facility design and costs
  • Contamination risk as assessed by the manufacturer
  • Design conditions versus operating range
  • Good engineering practice (GEP)
  • Enhanced documentation (1).

Proper balance of facility design and procedures. To achieve the proper balance of facility design and procedures, the guide addresses each GMP issue by facility design as well as through procedural control, facility layout, containment, and barrier technologies. This approach allows the flexibility to design for appropriate levels of protection or containment while avoiding costly designs that may result in no significant improvement in quality and efficacy of the drug product, or protection of personnel. For example, based upon an assessment of contamination risk within a tableting room, one or more of the following may be applied to prevent contamination:

  • Airlocks
  • Multiple pressurization levels
  • One-way personnel flow
  • Special gowning procedures
  • Special cleaning procedures (1).

Risk-based approach. The risk-based approach involves using innovative manufacturing science and technology to assess, mitigate, and control the potential hazard in a manufacturing process that affects the quality of the drug product. As an example, using statistical data analysis in conjunction with process analytical technology (PAT) for continuous process monitoring and control can lead to higher quality product. Sharing such risk-mitigation strategies with FDA may be beneficial (2).

Non-GMP technologies. Some facility-design requirements arise from decisions made to address non-GMP issues or preferences of the manufacturer such as operator safety or strategic-operating decisions. These non-GMP-driven technologies often affect facility-design features aimed at achieving GMP compliance (3). With proper planning, both GMP and non-GMP risk assessments may be completed in parallel, enabling key drivers for capital investment to be included in the project scope.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here